Thanks for taking my questions. One includes a uridine-containing messenger RNA, and the fourth vaccine candidate utilizes a self-amplifying mRNA. So in a nutshell, a benchmarking of the RBD and the spike domain for the self-amplifying mRNA [Inaudible] that the full-length spike is a better immunogen for the saRNA. Hey, guys. As Ugur previously mentioned, we made progress in our oncology clinical trials, and I'll lead you through key updates to our clinical pipeline, as shown on Slide 7. So we started the trial in April 21 in Germany and about two weeks later in the U.S. On July 27, 2020, BioNTech announced the closing of an underwritten offering of 5,500,000 American Depositary Shares (“ADSs”), each representing one of BioNTech… development and manufacturing services sold to third-party customers, retroviral vectors for clinical supply, and sales of peptides. Sorry. Total revenue, consisting primarily of revenue from collaborative agreements, was EUR 27.7 million for the three months ended March 31, 2020, compared to EUR 26.2 million for the three months ended March 31, 2019. Additional EUR 217 million in equity investments and non-dilutive upfront payments are due in the second quarter of 2020 from Pfizer and Fosun Pharma. Recently, BioNTech completed the acquisition of Neon Therapeutics, Inc. in an all-stock transaction. This week, we achieved an important milestone with the close of the acquisition of Neon Therapeutics. Thanks for taking my questions. There's 11 product candidates now in the clinic. BioNTech has also continued to advance its broad oncology pipeline. Second question with regards on -- yeah, yeah. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. You know that the German study is going to recruit about 200 subjects. A volunteer is injected with a vaccine as he participates in a coronavirus disease (COVID-19) vaccination study at the Research Centers of America, in Hollywood, Florida, U.S., September 24, 2020. We have rapidly advanced our COVID-19 program and started dosing patients in Europe and in the U.S. We look forward to having data in the coming months from these trials. So it will take a few more weeks until we have a full data set. The ultimate goal is to quickly identify a safe vaccine candidate that can prevent COVID-19. These forward-looking statements include but are not limited to the timing for enrollment and completion and reporting of data from our clinical trials and then potentially registration later of certain of our clinical trials and the impacts of the COVID pandemic on our business and our financial outlook. Find detailed technical information about the Pfizer-BioNTech vaccine, such as the product monograph and our regulatory decision summary, in the COVID-19 vaccines and treatments regulatory portal . 11, 2021 at 6:47 a.m. Our strategy is to utilize our suite of novel therapeutic platforms to fully exploit the potential of the immune system. And I think you haven't released the data from your basket study, so we were just wondering. I'll now hand the call over to Ugur Sahin, BioNTech's CEO. Next question is I noticed on your self-amplifying formulation you're choosing the full-length S protein as your antigen. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. In parallel, we are working closely with Pfizer to scale up manufacturing for global supply capacity, at risk, to provide worldwide supplies. What type of signals did you see in your early clinical data that made you confident that you wanted to explore that setting? It's a pleasure to welcome you to our first 2020 conference call. You are aware that we are always trying to have a deeply scientific publication not only showing preclinical data but providing also some sort of understanding, and therefore we expect that this will not happen in the next two months. And we have now several indications from -- also from the FixVac trial that patients with a lower tumor mass could be ideally suited for this type of vaccine and vaccine-checkpoint combination trials. Finally, as we outlined in our last call, we quickly implemented a three-point plan to manage the impact of the COVID-19 pandemic on our clinical programs. Finanzbericht 2. Both trials are currently enrolling healthy subjects between the ages of 18 to 55 and will target a dose range of at least one microgram to 100 microgram. And we believe that this patient, therefore, will particularly benefit with regard to their disease-free survival or -- and metastasis-free survival rates. Another objective is to get insights into the immunogenicity of our vaccine candidates in different subject groups across multiple regions. So that means also the information with regard to the immunogenicity and safety in subjects older than 55 will come with a certain setup delay. Both trials are recruiting now first subjects, and the number of subjects is accumulating. We have made significant progress toward our vision of bringing next-generation immunotherapies to patients. Perfect. We noticed one patient I think this patient seven. Ozlem Tureci will provide a brief pipeline update before handing the call over to Sierk Poetting, who will review our financial results and provide an update on our manufacturing-scale activities. BioNTech intends to initiate four Phase 2 trials (BNT111, BNT113, BNT122) and two additional FIH trials (BNT211, BNT411) in 2020. We aspire to utilize the full potential of the immune system to fight cancer and infectious diseases Then last question, sorry, for me. Finanzbericht 1. MUST CREDIT: Bloomberg photo by Alex Kraus. For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report on Form 20-F filed with the SEC on March 31, 2020, which … The first is on manufacturing. Please ask your question. BNT111 – Data from a Phase 1 trial in advanced melanoma remains on track for publication in late 1H 2020. To our knowledge, we are the only company currently in clinical testing with a vaccine targeting the RBD domain. Real time BioNTech SE (BNTX) stock price quote, stock graph, news & analysis. The drug candidate is a personalized neoantigen-targeted T cell therapy derived from patients' peripheral blood mononuclear cells or PBMCs consisting of multiple T cell populations targeting the most therapeutically relevant neoantigen from each patient's tumor. Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page of the Investor Relations section of the Company’s website at https://biontech.de/. So that's the overall strategy. We will now take our last question from the line of Robert Burns of H.C. Wainwright. So this is in regards to your update on BNT121. We expect that this data update will happen in the second half of 2020, yeah, most likely in the upcoming meeting, either ESMO or SITC. Pfizer, BioNTech sees 'dramatically' lower rates of COVID-19 in people vaccinated Mar. We have not seen any impact on our mRNA manufacturing, nor on our key manufacturing operations. And currently we are addressing everything what is required, including the supply chain to -- for manufacturing including nucleotides, lipids, enzymes and so on, to be able to deliver the scale that we have announced recently, yes. The Pfizer-BioNTech COVID-19 Vaccine is administered as a 2-dose series, 3 weeks apart, into the muscle. Cash Position: Cash and cash equivalents as of March 31, 2020, were €451.6 million. Hi. And this is Matthew on for Cory. It might be that we update on the recruitment of patients into this trial late 2020, but we will not provide substantial updates for the clinical trials in 2020 but most likely mid-2021. Thank you for joining us today for BioNTech's first-quarter 2020 update call. Also anticipate additional funding to support the manufact uring scale-up for our BNT162 program in 2020. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. BioNTech Says Ended Q1 With $495M In Cash, Sales €27.7M First Quarter 2020 Financial Results Cash Position: Cash and cash equivalents as of March 31, 2020, were €451.6 million. Our mRNA vaccine for COVID-19 exploits a highly potent lipid nanoparticle or LNP mRNA vaccine product. MAINZ, Germany, Aug. 11, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and infectious diseases, today provided an update on its corporate progress and reported financial results for the quarter ended June 30, 2020. We have seen strong evidence in the preclinical setting of its ability to amplify the effect of our vaccines as well. Hey, guys. Please ask your question. Thanks a lot, guys. BioNTech intends to initiate Phase 2 trials planned for end of 2020, manage ongoing Phase 1 trials to support completion and optimize ability to initiate and conduct FIH studies. Thank you. De werkzaamheid van het vaccin van BioNTech/Pfizer is boven verwachting goed bij ouderen. BioNTech expects to provide an enrollment update. The most recent coronavirus vaccine program, which we named Project Lightspeed, shows the speed and flexibility of our mRNA vaccine technology. SVB Leerink analyst D. Graybosch now forecasts that the company will post earnings of ($0.17) per share for the quarter, up from their prior estimate of ($0.18). And you've started to talk about this previously. Thank you. Yeah. We are pleased to report that Neon recently received a clinical trial authorization from the Dutch health authority for NEO-PTC-01, which we have now named BNT221. Data from this Phase 1/2 trial in multiple solid tumors is expected in the second half of this year. Further, our program is differentiated in that we are bringing vaccines against two distinct targets into clinical testing. These forward-looking statements are based on BioNTech’s current expectations and speak only as of the date hereof. The first quarter of 2020 has brought extraordinary challenges, and I am extremely proud of how we have -- as an organization have responded to these challenges. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. With the addition of BioNTech U.S. last week, we now have operations on both sides of the Atlantic. The first adjuvant Phase 2 study will evaluate the efficacy and safety of RO7198457 plus atezolizumab compared with atezolizumab alone in patients with Stage 2-3 non-small cell lung cancer (NSCLC) who are circulating tumor DNA (ctDNA) positive following surgical resection and have received standard-of-care adjuvant platinum-doublet chemotherapy. BioNTech will continue to evaluate potential effects and provide updates as appropriate. What I can share is an observation which we had already published for our melanoma trials showing that patients that -- with melanoma, even with a post-metastatic melanoma, could be controlled with the vaccine; and lack of relapses after application of iNeST. ET (2:00 p.m. CEST), BNT162 (Europe) - The first cohort of BioNTech’s Phase 1/2 clinical trial was dosed. The increase was mainly due to revenues resulting from other sales transactions i.e. BioNTech and Pfizer will work together to scale-up manufacturing capacity at risk to provide worldwide supply in response to the pandemic. Health Canada authorized this vaccine with conditions on December 9, 2020, under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. The increase was mainly due to revenues resulting from other sales transactions, i.e., development and manufacturing services sold to third-party customers, retroviral vectors for clinical supply and sales of peptides. General and Administrative Expenses: General and administrative expenses were €15.8 million for the three months ended March 31, 2020, compared to €9.3 million for the three months ended March 31, 2019. As the COVID-19 pandemic remains dynamic, we will continue to monitor the situation as it evolves then provide further updates accordingly. Cumulative Growth of a $10,000 Investment in Stock Advisor, BioNTech SE (BNTX) Q1 2020 Earnings Call Transcript @themotleyfool #stocks $BNTX, BioNTech SE (BNTX) Q3 2020 Earnings Call Transcript, BioNTech SE (BNTX) Q2 2020 Earnings Call Transcript, BioNTech SE (BNTX) Q4 2019 Earnings Call Transcript, Copyright, Trademark and Patent Information. Mensen van 60 jaar en ouder hebben het grootste risico op ernstige ziekte en sterfte door COVID-19. A replay of that event is available on our website, in the investor relations section, for those that missed it and would like to know additional details. Turning to Slide 8. And we expect that the dose of a potential active vaccine for uridine and self-amplifying RNA will be in the single-digit or even lower than single-digit concentration. The initial Phase 1 clinical trial of BNT221 will be in patients with metastatic melanoma who are not responsive to checkpoint inhibitors. There are currently ten oncology products in 11 ongoing trials with multiple data readouts expected in 2020. The second question, with regard to the preclinical publications. Q2. For questions on logistics, handling or other issues: service@biontech.de. I will start with a few introductory remarks about our quarterly and recent highlights. Safety, immunogenicity and tumor response data will be included. BioNTech SE (NASDAQ:BNTX)Q1 2020 Earnings CallMay 12, 2020, 5:00 p.m. “BioNTech has demonstrated significant progress to date in 2020. BNT162 - BioNTech’s vaccine program against COVID-19, BNT162, leverages the Company’s proprietary mRNA platform. Well, thank you, everyone, for joining the call. We plan to provide a further update on the expected trial design in the third quarter of 2020. Yeah, yeah. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Hi, Daina. LONDON — Before 2020, Germany's BioNTech was a relatively little-known biotechnology company. I think I just missed it and it's probably there in your slide, but could we get an update on time lines for data update for BNT312, your sialyl Lewis A antibody asset, please? We will announce a second indication which will come with the same rationale. The following slide deck was published by BioNTech SE in conjunction with their 2020 Q1 earnings call. As we previously noted, we have held discussions with regulatory authorities regarding next steps and the design of the Phase 2 trial. We are also working closely with Pfizer to ramp up our manufacturing capacity for global commercial supply. Thank you. With regard to 122, can you repeat your question? I wanted to start by quickly highlighting the significant progress we have made since the beginning of the year despite the ongoing COVID-19 pandemic.